New

Trackinsight is part of ETF One, the fully integrated ETF platform of Kepler Cheuvreux. Learn more →

Help us improve your experience. Please confirm your investor type:

ETF What's Up

Don’t Miss a Move in the ETF Market

Sign up and keep track of everything that moved the ETF industry this week. From new launches to regulatory shifts across the Atlantic.

ETF What's Up

You may unsubscribe at any time by clicking the “unsubscribe” link within the emailed newsletter. By signing up, you agree to our Privacy Policy and Terms and Conditions.

ETF screener

AAKG ETF · ARK Genomic Revolution UCITS ETF

The AAKG Exchange Traded Fund (ETF) is provided by ARK Invest Europe. This fund is actively managed; it does not track an index. The dividend policy is capitalization.
Real-time data unavailable for AAKG
LIVE
CLOSED
This fund is part ofWorld Blended Cap1M perf.+11.10%
Last price
N/A
1M perf.
+12.51%
1M flows
+€485K
AuM
€46M
E/R
0.75%
Rating
Not rated
ESG Consensus®
esg grade icon
AAKG
N/A

Performance & flows

Segment for quartile rank
February 2, 2026 → May 1, 2026
0-20-15-10-505%MARAPRMAYMARAPRMAY
Create a free account to view the flows graph
AAKG
$5.75
-0.15%
World Blended Cap
+4.99%

Historic performance and flows

1M3M1Y3Y5YMTDQTDYTD
Perf.
+12.51%
icon
-0.15%
icon
+41.89%
icon
N/AN/A
+1.53%
+15.22%
+6.05%
icon
Flows

Key fund info

Segment for quartile rank
Main characteristics
ISIN
IE000O5M6XO1
AuM
€46M
icon
E/R
0.75%
icon
ESG Consensus®
esg grade icon
icon
More details
NAV
5/1/2026
$5.75
1D NAV change
+1.53%
Dividend policy
No. of holdings
31
Inception date
4/12/2024
Jurisdiction
Ireland
Distribution
Denmark
Sweden
Finland
Germany
Ireland
Legal structure
Irish Collective Asset-management Vehicle
Base currency
USD
Classification
Product type
Asset class
Factors
N/A
Investment strategy
ARK Genomic Revolution UCITS ETF is an exchange-traded fund incorporated in Ireland. The Fund will invest in companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to genomics revolution.
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
half moonhalf moon double
New to Trackinsight?
For individual investors

Trackinsight
Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.
More fund data
Compare up to 3 funds
More screener filters
Choose your own screener columns from 100+ metrics
Lists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring
For professional investors

Trackinsight
Enterprise

Trackinsight Enterprise addresses the everyday operational, regulatory, and analytical pain points faced by professional and institutional ETF investors, from selection to execution.
Request a free trial
More professional services:ETF Data ServicesDue Diligence Services

Similar ETFs

ARKG
1M perf.
+11.98%
E/R
0.75%
XBI
1M perf.
+1.50%
E/R
0.35%
CURE
1M perf.
-2.34%
E/R
0.45%
XPH
1M perf.
+7.12%
E/R
0.35%
PTH
1M perf.
+2.30%
E/R
0.72%

Advertisement

Risk profile

Segment for quartile rank

Historical risk/return profile

3M1Y3Y5Y
Returns
-0.15%
icon
+41.89%
icon
N/A
N/A
Volatility
Perf./Volatility
Max drawdown
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
1
2
3
4
5
6
7
PRIIPS
1
2
3
4
5
6
7
More exposure metrics are available, exclusively in Trackinsight Enterprise

Exposure

Countries
USA
91.32%
Switzerland
8.68%
Sectors
Health Care
85.24%
Information Technology
1.20%
Unavailable
13.57%
Diversification
Total weight of top 15 holdings out of 31
Top 15 holdings
Data as of March 31, 2026
TWIST BIOSCIENCE CORP
CRISPR THERAPEUTICS
US88023B1035
BEAM THERAPEUTICS
10X GENOMICS INC
PERSONALIS INC
ILLUMINA
INTELLIA THERAPEUTICS INC
Create a free account to view top holdings
NATERA
CAREDX INC/D
RECURSION PHARMACEUTICALS
ABSCI
VERACYTE INC/D
GUARDANT HEALTH INC
NURIX THERAPEUTICS
Create a free account to view top holdings
More risk metrics are available, exclusively in Trackinsight Enterprise

Sustainability

Integrates ESG criteria
Yes
SDG
More sustainability metrics are available, exclusively in Trackinsight Enterprise

Issuer

ARK Invest Europe
ARK Invest Europe ID Card
Number of funds
10
Total AuM
€948M
Expense ratio range
0.45% - 0.75%
Average expense ratio
0.58%

The details about this provider will be added soon.

Frequently asked questions about AAKG

What does ARK Genomic Revolution UCITS ETF, AAKG, invest in?

AAKG is a Active ETF. This ETF provides exposure to Other Equities.

What is the Total Expense ratio (TER) of AAKG?

AAKG carries a total expense ratio (TER) of 0.75%, indicating the annual cost for holding the fund.

When was AAKG launched?

AAKG was introduced to the market on April 12, 2024. It trades on Denmark, among other exchanges

Who is the ETF issuer of AAKG?

ARK Genomic Revolution UCITS ETF, AAKG, is provided by ARK Invest Europe. Learn more about ARK Invest Europe here.

What is the current assets under management (AUM) of AAKG?

AAKG oversees €46M in assets as of May 1, 2026.

How has AAKG performed lately?

Based on data from May 1, 2026, AAKG returned 12.51% over the past month, -0.15% over the last three months and 6.05% year-to-date.

What are the latest inflows or outflows for AAKG?

As of May 1, 2026, AAKG recorded net flows of +€484K over the last month and +€6.6M year-to-date.

Does AAKG distribute dividends?

AAKG follows a capitalizing, meaning it reinvests income within the fund.

What are the main country or region exposures of AAKG?

As of March 31, 2026, AAKG has significant geographic allocations in USA and Switzerland.

In which sector or theme does AAKG invest in?

As of March 31, 2026, AAKG focuses largely on Health Care and Information Technology.

How many securities does AAKG hold and how diversified is it?

As of March 31, 2026, AAKG holds 31 positions in its portfolio, with 74.87% of assets concentrated in its top 15 holdings.

What are the main positions in AAKG?

As of March 31, 2026, AAKG top three holdings include TWIST BIOSCIENCE CORP, CRISPR THERAPEUTICS and US88023B1035.

What is the base currency of AAKG?

The base currency of AAKG is USD.

Advertisement

Trackinsight

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy  |  Cookie policy  |    |  Terms of use  |  Imprint
Trackinsight